Skip to Content

Join the 'Deep Vein Thrombosis' group to help and get support from people like you.

Deep Vein Thrombosis News

Testosterone Therapy May Be Linked to Serious Blood Clots

Posted 1 day 16 hours ago by Drugs.com

WEDNESDAY, Nov. 30, 2016 – Testosterone treatment can increase a man's risk of potentially fatal blood clots, a new study suggests. Researchers found that men taking the male hormone seem to have a 63 percent increased risk of a blood clot forming in a vein, a condition known as venous thromboembolism (VTE). These clots can cause a heart attack, stroke, organ damage or even death, according to the American Heart Association. "Risk peaks rapidly in the first six months of treatment and lasts for about nine months, and fades gradually thereafter," said lead researcher Dr. Carlos Martinez of the Institute for Epidemiology, Statistics and Informatics in Frankfurt, Germany. Millions of American men currently use testosterone pills, gels or injections, hoping that the male hormone will boost their sex drive, stamina and strength. It's been known for a while that the estrogen in birth control ... Read more

Related support groups: Bleeding Disorder, Testosterone, Deep Vein Thrombosis (DVT), AndroGel, Testim, Deep Vein Thrombosis, Axiron, Androderm, Depo-Testosterone, Testopel, Fortesta, Sexual Deviations or Disorders, Hypoactive Sexual Desire Disorder, Testopel Pellets, Venous Thromboembolism, Testim 5 g/packet, Coagulation Defects and Disorders, Delatestryl, Testosterone Topical, Striant

C-Section Raises Risk of Blood Clots After Childbirth: Review

Posted 4 Oct 2016 by Drugs.com

TUESDAY, Oct. 4, 2016 – Women who have a cesarean section face an increased risk of potentially dangerous blood clots in the legs or lungs following childbirth, a new review confirms. Researchers who analyzed 60 international studies found that women who had a C-section were four times more likely to develop a blood clot than women who delivered vaginally. "Emergency" C-sections – which are done when a vaginal delivery fails – carried the highest risk. Experts said the findings confirm what individual studies have already shown. It has long been clear that pregnancy itself raises a woman's odds of developing blood clots before or in the weeks after delivery. Women who undergo a C-section have an even greater risk – though it's still low, according to the researchers behind the new study. The new study estimates the risk is about three in 1,000. "Even though C-section increases the ... Read more

Related support groups: Blood Disorders, Bleeding Disorder, Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Deep Vein Thrombosis - First Event, Delivery, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Deep Vein Thrombosis - Prophylaxis, Cesarean Section, Labor and Delivery including Augmentation

Is Binge-Watching Hazardous to Your Health?

Posted 26 Jul 2016 by Drugs.com

MONDAY, July 25, 2016 – Binge-watchers, beware: Too much time in front of the TV could boost your risk of death from a blood clot in the lung, researchers warn. A lung blood clot (pulmonary embolism) typically begins as a clot in the leg or pelvis that develops due to inactivity and reduced blood flow. The clot can break free and travel to a lung and lodge in a small blood vessel, posing a serious threat. This new study included more than 86,000 people in Japan, aged 40 to 70. They were asked how many hours they spent watching television and then were followed for 19 years. During that time, 59 participants died of a pulmonary embolism. Compared to those who watched less than 2.5 hours of television a day, the risk of dying from pulmonary embolism increased 70 percent among those who watched 2.5 to 4.9 hours daily. It was 40 percent greater for each additional two hours of television ... Read more

Related support groups: Blood Disorders, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Pulmonary Embolism - First Event, Deep Vein Thrombosis, Deep Vein Thrombosis - First Event, Deep Vein Thrombosis - Recurrent Event, Pulmonary Embolism - Recurrent Event, Deep Vein Thrombosis - Prophylaxis, Coagulation Defects and Disorders

Health Tip: Know Your Risk for Deep Vein Thrombosis

Posted 4 Aug 2015 by Drugs.com

-- A dangerous condition called deep vein thrombosis (DVT) occurs when a blood clot develops in a vein deep inside the body. The U.S. National Heart Lung and Blood Institute mentions these potential risk factors: Having had a previous DVT, or taking medication that thickens the blood or promotes clotting. Having had surgery, a broken bone or other injury that affects a deep vein. Having reduced blood flow to a deep vein as a result of inactivity. Typical causes are post-surgical recovery, or taking a long trip that limits your ability to move around. Being pregnant. Being treated for cancer. Having a central venous catheter. Being over the age of 60, being a smoker or being obese. Read more

Related support groups: Blood Disorders, Warfarin, Coumadin, Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Lovenox, Eliquis, Deep Vein Thrombosis, Heparin, Deep Vein Thrombosis - First Event, Deep Vein Thrombosis - Recurrent Event, Rivaroxaban, Enoxaparin, Clexane, Apixaban, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Fragmin, Arixtra, Hep-Pak

FDA Approves Savaysa (edoxaban) to Prevent Embolic Events in Non-Valvular Atrial Fibrillation

Posted 12 Jan 2015 by Drugs.com

January 8, 2015 – The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. Atrial fibrillation is one of the most common types of abnormal heart rhythm. It occurs when the heart’s two upper chambers (atria) do not contract properly, allowing blood clots to form, which can break off and travel to the brain or other parts of the body. Patients with atrial fibrillation experience an abnormal, irregular and rapid heartbeat. Savaysa also has been approved to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already been treated with an anti-clotting drug administered by injection or infusion (parenterally), for five to ten days. DVT is a blood clot that f ... Read more

Related support groups: Atrial Fibrillation, Pulmonary Embolism, Deep Vein Thrombosis, Prevention of Thromboembolism in Atrial Fibrillation

Common Painkillers Tied to Blood Clot Risk, Study Suggests

Posted 24 Sep 2014 by Drugs.com

WEDNESDAY, Sept. 24, 2014 – People who use painkillers called nonsteroidal anti-inflammatory drugs (NSAIDs) – which include aspirin, naproxen (Aleve) and ibuprofen (Advil, Motrin) – may be at increased risk for potentially deadly blood clots, a new study suggests. But the study only showed an association between use of the painkillers and higher clotting risk; it did not prove cause-and-effect. The researchers analyzed the results of six studies involving more than 21,000 cases of a type of blood clot called a venous thromboembolism (VTE). These clots include deep vein thrombosis (a clot in the leg) and pulmonary embolism (a clot in the lungs). Reporting online Sept. 24 in Rheumatology, the analysis found that people who used NSAIDs had an 80 percent higher risk for venous clots. "Our results show a statistically significant increased VTE risk among NSAID users. Why NSAIDs may ... Read more

Related support groups: Aspirin, Ibuprofen, Naproxen, Advil, Deep Vein Thrombosis (DVT), Aleve, Motrin, Pulmonary Embolism, Deep Vein Thrombosis, Naprosyn, Ecotrin, Vioxx, Naprelan '375', Bayer Aspirin, Naprelan, Anaprox, Anaprox-DS, Bufferin, Ibuprofen PMR, Motrin Childrens

Most Treatments for Blood Clots Appear Safe, Effective

Posted 16 Sep 2014 by Drugs.com

TUESDAY, Sept. 16, 2014 – Almost all the various treatment options for blood clots that form in veins are equally safe and effective, new research shows. In exploring the safety and effectiveness of treatments for such blood clots as deep vein thrombosis or pulmonary embolism (blood clot in a lung), Canadian researchers analyzed outcomes associated with eight blood-thinning options, including unfractionated heparin, low-molecular-weight heparin (LMWH) and fondaparinux in combination with vitamin K antagonists. The investigators also examined LMWH with dabigatran (Pradaxa), edoxaban, rivaroxaban (Xarelto), apixaban (Eliquis), as well as LMWH alone. After examining nearly 50 randomized studies, the researchers found that unfractionated heparin combined with vitamin K antagonist was associated with a higher percentage of recurrent blood clots over the course of three months than the ... Read more

Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Pulmonary Embolism, Eliquis, Deep Vein Thrombosis, Heparin, Rivaroxaban, Apixaban, Thrombotic/Thromboembolic Disorder, Arixtra, Hep-Pak, Fondaparinux, Dabigatran, Venous Thromboembolism, Heparin Sodium, Pulmonary Thromboembolism, Arixtra 5 mg/dose, Arixtra 10 mg/dose, Arixtra 7.5 mg/dose

Study: Aspirin Might Work Instead of Warfarin for Deep Vein Clots

Posted 26 Aug 2014 by Drugs.com

TUESDAY, Aug. 26, 2014 – Aspirin may offer an alternative for people who've had blood clots in the deep veins of the legs and can't tolerate long-term use of blood thinners, according to Australian researchers. The condition, called deep vein thrombosis (DVT), can be life-threatening if clots break loose, travel to the lungs and block a pulmonary artery. Patients are usually prescribed blood thinners such as warfarin to prevent clot formation, the researchers noted. "Most people who have had a blood clot in a leg vein or an embolism where the clot blocks the blood flow have anticoagulant drug treatment, such as warfarin, for at least six months, first to dissolve the clot and then to prevent it happening again," said lead researcher Dr. John Simes, a professor of medicine at the University of Sydney. However, long-term use of warfarin (Coumadin) can be inconvenient, requiring frequent ... Read more

Related support groups: Aspirin, Warfarin, Coumadin, Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Deep Vein Thrombosis, Rivaroxaban, Ecotrin, Bayer Aspirin, Dabigatran, Jantoven, Bufferin, Low Dose ASA, Fasprin, Aspergum, Buffered Aspirin, Ascriptin, Easprin, ZORprin

FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism

Posted 24 Aug 2014 by Drugs.com

Thursday, August 21, 2014 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE. It is estimated that every year, approximately 900,000 Americans are affected by DVT and PE. “We are pleased that Eliquis is now available as an effective treatment option for DVT and PE,” said Douglas Manion, M.D., Head of Specialty Development, Bristol-Myers Squibb. “Eliquis offers oral dosing, no routine coagulation testing, and does not require the use of a parenteral anticoagulant or bridging during initiation.” “DVT, which may lead to PE, can be a serious medical condition, with PE requiring immediate med ... Read more

Related support groups: Pulmonary Embolism, Eliquis, Deep Vein Thrombosis, Apixaban, Venous Thromboembolism

Preemies May Have Higher Risk of Blood Clots, Even as Adults

Posted 28 Jul 2014 by Drugs.com

MONDAY, July 28, 2014 – Babies born prematurely appear to have a slightly increased risk of potentially fatal blood clots that they will carry into adulthood, Swedish researchers report. Doctors have previously suspected that babies born earlier than 37 weeks' gestation have a raised risk of deep vein thrombosis and pulmonary embolism, two serious conditions caused by blood clotting in the veins, the researchers noted in background information. This new study confirms that link, and takes it even further. Premature birth appears to be linked to an increased chance of blood clots in the veins in childhood and early adulthood, according to findings published online July 28 in the journal Pediatrics. The researchers also reported that a baby's chances of blood clot-related illnesses are directly related to the degree of prematurity. "The more premature, the higher the risk," said Dr. ... Read more

Related support groups: Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Prematurity/Underweight in Infancy

Study Casts Doubt on Costly Treatment for Leg Clots

Posted 22 Jul 2014 by Drugs.com

TUESDAY, July 22, 2014 – Two treatments that break up blood clots deep in the veins of the legs appear no different in terms of death risk. However, one results in a greater risk of bleeding and average hospitalization bills that are three times the cost of the other treatment, a new study finds. The standard treatment for these clots – known as deep vein thrombosis (DVT) – is blood-thinning medications and compression stockings. The other, more expensive treatment delivers medication directly to the clot to dissolve it. This procedure, called catheter-directed thrombolysis, has increased in use in recent years despite inconclusive research as to its safety, the study authors said. "DVT is a very common disease that occurs in about one in 1,000 people per year," said lead researcher Dr. Riyaz Bashir, an associate professor of medicine at Temple University School of Medicine in ... Read more

Related support groups: Deep Vein Thrombosis (DVT), Deep Vein Thrombosis

FDA Approves Pradaxa for Deep Venous Thrombosis and Pulmonary Embolism

Posted 7 Apr 2014 by Drugs.com

Ridgefield, CT, April 7, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). There are an estimated 900,000 DVT and PE events per year in the U.S., approximately one-third of which result in death from PE. “Venous thromboembolism is the third most common cardiovascular disease after myocardial infarction and stroke. About one-third of patients with a DVT or PE will suffer a recurrence within 10 years,” said Samuel Z. Goldhaber, M.D., Director of ... Read more

Related support groups: Pradaxa, Pulmonary Embolism, Deep Vein Thrombosis, Dabigatran

Pricey New Blood Thinner Eliquis Might Be Safer for Leg Clots

Posted 1 Jul 2013 by Drugs.com

MONDAY, July 1 – The new pill Eliquis prevents dangerous blood clots in the legs and lungs as well as standard therapy, though with less risk of serious bleeding, a new study shows. The research, published online July 1 in the New England Journal of Medicine, may point doctors toward a simpler, if more costly, way to prevent repeat blood clots in patients at risk for venous thromboembolism. Venous thromboembolism includes two related conditions: deep vein thrombosis (DVT) and pulmonary embolism. Together, these conditions hospitalize more than 500,000 adults each year in the United States, according to the government's National Hospital Discharge Survey. In DVT, a blood clot forms in the deep veins of the leg, causing swelling, redness, warmth and pain. If the blood clot breaks free, it can travel and lodge near the brain, heart or another vital organ, causing severe damage. If a clot ... Read more

Related support groups: Deep Vein Thrombosis (DVT), Eliquis, Deep Vein Thrombosis

Study Probes Use of Filter Device to Stop Deadly Blood Clots

Posted 18 Mar 2013 by Drugs.com

MONDAY, March 18 – The use of a special filter to prevent potentially deadly blood clots from traveling to patients' lungs varies widely among hospitals, a new study finds. A vena cava filter is placed in the inferior vena cava, the large vein in the abdomen that returns blood from the lower body to the heart. It is one of the treatments for people with blood clots that develop in the veins of the leg or pelvis (deep vein thrombosis). These blood clots can break free and travel to the lungs, where they can cause severe complications or death. A vena cava filter, which is designed to trap these clots before they reach the lungs, may be the only treatment option for patients who can't be given blood-thinning drugs. But one expert notes that the evidence around the effectiveness of these devices has never been clear. "Vena cava filters were once thought to be lifesaving devices in ... Read more

Related support groups: Deep Vein Thrombosis (DVT), Deep Vein Thrombosis

New Blood Thinner Beats Older Drug for Vein Clots: Study

Posted 20 Feb 2013 by Drugs.com

WEDNESDAY, Feb. 20 – People who need to take a blood thinner because they've had a clot in the deep veins of their legs appear to do better with the new drug Pradaxa (dabigatran) than with the older drug warfarin, researchers report. Long-term treatment of these blood clots is safer and more convenient with Pradaxa than warfarin, the new study found. Extended treatment with blood thinners after clots develop in the veins or the lungs should be considered more often than it is, said lead researcher Dr. Sam Schulman, a professor in the division of hematology and thromboembolism at McMaster University in Hamilton, Ontario, Canada. If a clot in the leg breaks loose and travels to the heart, brain or lungs, it can cause a heart attack, stroke or a pulmonary embolism – all of which can be fatal. People taking warfarin need periodic blood tests to be sure they aren't getting too much of the ... Read more

Related support groups: Warfarin, Coumadin, Deep Vein Thrombosis (DVT), Pradaxa, Deep Vein Thrombosis, Jantoven, Dabigatran

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Deep Vein Thrombosis - Prophylaxis, Deep Vein Thrombosis - Recurrent Event, Deep Vein Thrombosis - First Event, Venous Thromboembolism

Related Drug Support Groups

Xarelto, Pradaxa, Lovenox, Eliquis, heparin, rivaroxaban, enoxaparin, apixaban, Clexane, view more... Arixtra, fondaparinux, Innohep, dabigatran, streptokinase, tinzaparin, Heparin Sodium, urokinase, Savaysa, edoxaban, Arixtra 10 mg / dose, Kinlytic, Streptase, Abbokinase, Kabikinase, Abbokinase Open-Cath, Lovenox HP, Arixtra 5 mg / dose, Clexane Forte, Arixtra 7.5 mg / dose